Company expects existing supply will suffice to complete clinical trial and lead to cost savings

HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).